← brief for 2026-08-13 · Slowing decline

Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes.

Article B Peer reviewed Small trial

Key takeaways

SGLT2 inhibitors showed better kidney outcomes in patients with diabetes than those without. The study followed 132 patients for 12 months. This suggests SGLT2 inhibitors may be more effective in group with diabetes, but results should be interpreted with caution.

Who did this work

Capelli I · Vetrano D · Ribichini D · Provenzano M · Albertini S · Berti S · Sanfilippo I · Vicennati V · Pagotto U · La Manna G · Cianciolo G

Source

Article · PubMed, the drug frontier · 2026 Aug 12
https://pubmed.ncbi.nlm.nih.gov/42592709/